Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05809284

Determining the Mechanisms of Loss of CAR T Cell Persistence — CARPERS  

Acute Lymphoblastic Leukemia, in Relapse Clinical Trial

Official title:
Determining the Mechanisms of Loss of CAR T Cell Persistence

Clinical Trial Summary

A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Acute Lymphoblastic Leukemia Not Having Achieved Remission
  • Acute Lymphoblastic Leukemia With Failed Remission
  • Acute Lymphoblastic Leukemia, Adult
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia, Pediatric
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical Trial Details
NCT number NCT05809284
Study type Observational
Source University College, London
Contact CARPERS Trial Manager
Phone 442031084189
Email ctc.carpers@ucl.ac.uk
Status Recruiting
Phase
Start date October 18, 2023
Completion date December 1, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05066958 - Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT Phase 1/Phase 2
Completed NCT04224571 - CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children Phase 2
Recruiting NCT04888442 - Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL Phase 1
Recruiting NCT04049383 - CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL Phase 1
Not yet recruiting NCT05745714 - HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Phase 1/Phase 2
Withdrawn NCT05740449 - HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Phase 1/Phase 2
Not yet recruiting NCT06213636 - Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). Phase 1/Phase 2
Recruiting NCT04603872 - CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies Early Phase 1
Recruiting NCT04475731 - Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse Phase 2
Recruiting NCT06445803 - CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL Phase 1
Recruiting NCT03957915 - Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia Early Phase 1
Terminated NCT03705507 - International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia Phase 1/Phase 2
Recruiting NCT04325841 - Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children Phase 2
Recruiting NCT04340167 - Study of Anti-CD22 CAR-T Cells Treating Leukemia Children Phase 2
Recruiting NCT04605666 - CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia Phase 2
Active, not recruiting NCT04340154 - Study of Sequential CAR-T Cell Treating Leukemia Children Phase 2
Recruiting NCT05292664 - Venetoclax Basket Trial for High Risk Hematologic Malignancies Phase 1
Recruiting NCT06316427 - Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma Phase 1/Phase 2
Recruiting NCT05310591 - Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence Phase 1/Phase 2
Not yet recruiting NCT05705570 - A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies Phase 1